Inhibrx Biosciences, Inc. - Common Stock When Issued INXBV 深 滬
已收盤 05-29 16:00:00 美东时间
13.92
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 13.92
- 總市值 2.02亿
- 52周最高 16.00
- 市盈率 靜 0.12
- 換手率 0.00%
- 52周最低 12.95
- 委 比 0.00%
- 總股本 1447.59万
- 歷史最高 16.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 12.95
- 每 手 1
- 風險率 6.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea
<p>Incannex Healthcare's Phase 2 RePOSA trial for IHL-42X in treating obstructive sleep apnoea (OSA) shows promising results. Exit interviews reveal 57.6% of participants experienced improved sleep quality and reduced daytime fatigue. Clinical data highlights up to 83% reduction in Apnoea-Hypopnoea Index (AHI). The drug maintains REM sleep, unlike many approved sleep medications, and demonstrates an excellent safety profile with no serious advers...
08-08 12:00
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo
Incannex Healthcare Inc. announce the appointment of Dr. Charlene E. Gamaldo to its IHL-42X OSA Clinical Advisory Board. Dr. Gamaldo, a renowned expert in neurology, psychiatry, and sleep medicine, brings significant expertise to support the development of IHL-42X, a drug targeting the underlying pathophysiology of obstructive sleep apnea (OSA). IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide currently in Phase 2/3 clini...
07-25 11:30
Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
Incannex Healthcare achieved database lock for its RePOSA Phase 2 trial of IHL-42X, a potential first-in-class treatment for obstructive sleep apnoea (OSA), on June 16, 2025. This milestone enables final statistical analysis to begin, with top-line results expected in July 2025. IHL-42X, a fixed-dose combination of dronabinol and acetazolamide, targets the underlying pathophysiology of OSA by addressing intermittent hypoxia and hypercapnia. The d...
06-18 11:30
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
Incannex Healthcare Inc. and Mind Medicine Australia (MMA) have formed a 50:50 joint venture to operate a psychedelic-assisted therapies clinic in Melbourne. The partnership aims to enhance access and scalability for treatments targeting PTSD, treatment-resistant depression, and other mental health conditions. The new entity, Mind Medicine Australia Clinics, will provide integrated clinical services, including medical oversight and training, to e...
06-17 11:30
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
Incannex Healthcare Inc. has appointed four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board, including Scott A. Sands, Ph.D., Ali Azarbarzin, Ph.D., Lora J. McGill, M.D., and Nancy Collop, M.D., to advance its development of IHL-42X, an oral once-daily treatment for OSA. This expansion underscores Incannex's commitment to addressing a major health concern as it prepares to announce Phase 2 topline data i...
06-03 11:30
Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results
Incannex Healthcare Inc. has entered into a binding agreement to cancel the remaining 172 million Series A Warrants, paying up to $12.2 million to holders, eliminating up to 347.2 million shares from potential dilution. This follows an earlier cancellation of 175.2 million shares. The move strengthens the company's capital structure and addresses dilution risks. The agreement coincides with the upcoming release of topline data from the Phase 2 Re...
05-28 11:00
